SYR-472 Open-label Study
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 26 Mar 2015 According to Takeda Pharmaceuticals media release, based on the results of this and other phase III trials ( see profile 219690 and 206116), Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of Zafatek (trelagliptin succinate).
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2013 New trial record